Acticor Biotech

Acticor Biotech FCF Yield

Delisted

The Free Cash Flow Yield of Acticor Biotech (ALACT.PA) as of Nov 7, 2026 is -331.14 %. In the previous year, Free Cash Flow Yield was -307.36 % — a change of 7.74% (lower).

FCF Yield

-331.14 %

YoY

7.74%

Last updated:

Free Cash Flow Yield of Acticor Biotech is 2023 -331.14 % . Free Cash Flow Yield of Acticor Biotech was 2022 -307.36 % . It decreases by 7.74% lower compared to the previous year.

The Acticor Biotech FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2016
-11.38 EUR
Jan 1, 2017
-14.71 EUR
Jan 1, 2018
-27.84 EUR
Jan 1, 2019
-108.96 EUR
Jan 1, 2020
-172.39 EUR
Jan 1, 2021
-349.31 EUR
Jan 1, 2022
-307.36 EUR
Jan 1, 2023
-331.14 EUR
The Acticor Biotech FCF Yield history
YEARFCF YieldYoY
-331.14 %+7.74%
-307.36 %-12.01%
-349.31 %+102.64%
-172.39 %+58.21%
-108.96 %+291.45%
-27.84 %+89.28%
-14.71 %+29.21%
-11.38 %-91.47%
-133.42 %-358.78%
51.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acticor Biotech Stock analysis

What does Acticor Biotech do? Acticor Biotech SA develops antithrombotic agents for acute thrombotic diseases, focusing on acute ischemic strokes and pulmonary embolisms. The company has one product, Glenzocimab, in Phase II clinical development, alongside pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN. It collaborates with partnering companies Ouest Valorisation, Genopole, Medicine, and Inserm for research and development. Acticor Biotech SAS is a clinical stage biopharmaceutical company spun off from INSERM, with 24 full-time employees. The firm generates revenue through its research and development activities, leveraging its partnership with INSERM and other institutions. Glenzocimab, its lead product, is in Phase II trials, indicating potential future licensing agreements or sales. The company's pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN represent additional revenue streams once they progress through clinical development. Acticor Biotech targets the biopharmaceutical sector, specifically focusing on thrombotic disease treatments. Its primary customers are pharmaceutical companies seeking to license or co-develop novel antithrombotic therapies. The company's partnerships with Ouest Valorisation, Genopole, Medicine, and Inserm facilitate its R&D efforts and potential commercialization pathways. Acticor Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acticor Biotech stock

Free Cash Flow Yield of Acticor Biotech is -331.14 % in 2023.

Free Cash Flow Yield of Acticor Biotech changed from -307.36 % to -331.14 %, representing a 7.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Acticor Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Acticor Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Acticor Biotech

All Key Metrics — Acticor Biotech